Aptamer-Drug Conjugates

Theme-4.png
No.
Principle Investigator(s)
Title
Project Id (Funding Body)
1
Prof. Aiping Lu
Toward the next generation of smart anti-tumor drugs: a highly water-soluble nucleolin aptamer-paclitaxel conjugate with a serum-stable linker for tumor-specific targeting in ovarian cancer (2019.1.1-2021.6.30, HK$697,734)
HKBU 12102518 (GRF/RGC)
2
Prof. Ge Zhang
From precision medicine to drug discovery: osteoblast-specific inhibition of Smurf1 activity promotes bone formation in distinctive rats with age-related osteoporosis (2019.1.1-2021.12.31, HK$971,481)
HKBU 12100918 (GRF/RGC)
3
Prof. Ge Zhang
An innovative immuno-chemotherapy for triple-negative breast cancer: PD-L1 aptamer-paclitaxel conjugate. Funding Body: Science and Technology Innovation Commission of Shenzhen Municipality (2019.1.1-2021.12.31, RMB3,000,000)
SCM-2016-SZTIC-001 (Science and Technology Innovation Commission of Shenzhen Municipality)
4
Prof. Aiping Lu
Strategic Development of Aptamer-based Drug Discovery Platform (2018.1.1-2019.12.31, HK$5,000,000)
SDF16-0603-P02 (HKBU-RC)
5
Prof. Aiping Lu
Toward precision medicine in aged osteoporotic subgroup with poor BMP responsiveness: Oligopeptide-chalcone derivative conjugate targeting osteoblasts for Smurf1 inhibition and bone formation enhancement (2018.01-2020.12, HK$1,998,900)
RC-ICRS/16-17/01 (HKBU-RC)
6
Prof. Aiping Lu
Does aberrantly overexpressed CKIP-1 suppress osteoblast-mediated articular bone repair in inflammatory arthritis? A collagen-induced non-human primate arthritis model (2017.1.1-2019.6.30, HK$795,400)
HKBU 12122516 (GRF/RGC)
7
Prof. Ge Zhang, Prof. Hong Zhou
Bone formation surfaces-targeted delivery of 11β-HSD1 inhibitor to protect against high-fat diet-induced obesity
Pending
Title